Arovella Therapeutics Limited

Equities

ALA

AU0000182784

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:23 23/05/2024 BST			5-day change	1st Jan Change
0.11 ^AUD	+4.76%		0.00%	-4.35%

03-26	Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	MT
03-20	Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	MT

Arovella Therapeutics Ltd Announces Executive Changes

November 09, 2021 at 10:35 pm

Arovella Therapeutics Ltd. announced that David Phillips is stepping down from his role as Head of Business Development, and will continue as a Board Director until 14 January 2022. Mr. Phillips joined Arovella as consultant in 2017 and headed up the Business Development function in 2018, playing an important role in structuring partnerships for the OroMist platform since that time. Arovella's CEO an MD, Dr. Michael Baker will assume the role in the interim.

Latest news about Arovella Therapeutics Limited

Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	03-26	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	03-20	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License	01-30	MT
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%	01-02	MT
Arovella Therapeutics Ltd. Announces Change of Company Address	12-06	CI
Arovella Therapeutics Appoints CFO	12-01	MT
Arovella Therapeutics Limited Announces Changes to its Board	12-01	CI
Arovella Therapeutics Limited Announces Executive Changes	12-01	CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023	11-20	MT
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady	12/10/23	MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%	12/10/23	MT
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director	07/09/23	CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan	11/07/23	MT
Arovella Therapeutics Extends Closing Date of Share Purchase Plan	29/06/23	MT
Arovella Therapeutics, UNC Further Discussions on Enhanced iNKT Cells Performance	26/06/23	MT
Arovella Therapeutics Ends AU$4.1 Million Placement; Launches AU$1 Million Purchase Plan	07/06/23	MT
Arovella Therapeutics Completes Closure of Perth R&D Facility	01/05/23	MT
Arovella Therapeutics Appoints Nonexecutive Chair	13/03/23	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23	CI
Arovella, Imugene's Collaboration on Tumor Cells Therapy Progresses to Next Phase	10/02/23	MT
Arovella Therapeutics Limited and Imugene Announces Collaboration Advances to Next Phase of Testing	09/02/23	CI
Arovella Therapeutics Appoints COO	04/01/23	MT
Arovella Therapeutics Ltd Appoints Dr. Nicole Van Der Weerden as Chief Operating Officer, January 4, 2023	03/01/23	CI

Chart Arovella Therapeutics Limited

Duration

Period

More charts

Company Profile

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROVELLA THERAPEUTICS LIMITED	-4.35%	73.21M
MODERNA, INC.	+63.58%	62.59B
IQVIA HOLDINGS INC.	-2.06%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.25%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.75%	19.09B
BIO-TECHNE CORPORATION	+3.60%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.40%	12.26B
MEDPACE HOLDINGS, INC.	+27.31%	12.05B

Other Biotechnology & Medical Research